8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 8, 2026·SEC
Material company update
Mar 3, 2026·SEC
STAAR Surgical Company(STAA)Earnings, Financials & Key Ratios
STAA•NASDAQ
$26.55
Price updated Jul 7, 2026
AboutSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.Show more
- Revenue$239M-23.7%
- EBITDA-$37M-550.7%
- Net Income-$80M-298.1%
- EPS (Diluted)-1.62-295.1%
- Gross Margin76.19%-0.2%
- EBITDA Margin-15.54%-753.0%
- Operating Margin-19.19%-377.6%
- Net Margin-33.6%-421.9%
- ROE-21.7%-320.5%
STAA Price & Volume
STAAR Surgical Company (STAA) stock price & volume — 10-year historical chart
Loading chart...
Volatile Revenue Growth Masks Persistent Operational Losses
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Burning
Primary Risk:Geographic revenue concentration risk
Key Thesis Takeaways
- STAAR Surgical maintains a durable competitive advantage through its proprietary Collamer lens technology, evidenced by consistent gross margins near 75%.
- However, the company faces significant challenges in achieving sustainable operating leverage, as evidenced by SG&A expenses that frequently exceed gross profit and lead to recurring net losses.
- Investors should monitor the company's ability to stabilize its erratic cash flow, which recently swung to a negative $22.1 million in 2026Q1, against its current $131.9 million cash position.
Verdict Logic
while the company maintains a healthy current ratio of 5.12, the persistent inability to generate positive free cash flow, which reached -$22.1 million in 2026Q1, warrants a cautious wait-and-see approach.
STAA Growth Metrics
STAAR Surgical Company (STAA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12%
5 Years7.93%
3 Years-5.57%
TTM4.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM70.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM70.83%
Return on Capital
10 Years0.13%
5 Years3.87%
3 Years-2.29%
Last Year-11.04%
STAA Recent Earnings
STAAR Surgical Company (STAA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.38+600.8%
$0.05
Rev
$94M+18.8%
$79M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.20-211.1%
$0.18
Rev
$58M-22.9%
$75M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.46+155.6%
$0.18
Rev
$95M+25.4%
$76M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.07+87.5%
$0.56
Rev
$44M-50.3%
$89M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.38vs $0.05+600.8% | $94Mvs $79M+18.8% |
| Q2 2026 | Mar 3, 2026 | $0.20vs $0.18-211.1% | $58Mvs $75M-22.9% |
| Q4 2025 | Nov 5, 2025 | $0.46vs $0.18+155.6% | $95Mvs $76M+25.4% |
| Q3 2025 | Aug 6, 2025 | $0.07vs $0.56+87.5% | $44Mvs $89M-50.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for STAAR Surgical Company (STAA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $26.55 | $1.32B | -16.39 | -23.72% | -33.6% | -21.7% | — | |
| $185.22 | $13.26B | 32.78 | 0.9% | 10.5% | 10.7% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $71.12 | $2.46B | 14.60 | 37.13% | 27.04% | 41.92% | — | |
| $94.82 | $54.6B | 51.81 | 11.55% | 17.34% | 10.54% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — |
Compare STAA vs Peers
STAAR Surgical Company (STAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STAA SEC Filings & Documents
STAAR Surgical Company (STAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when STAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STAA Frequently Asked Questions
STAAR Surgical Company (STAA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is STAAR Surgical Company's revenue?
STAAR Surgical Company (STAA) reported $290.4M in revenue for fiscal year 2025. This represents a 588% increase from $42.2M in 1996.
How fast is STAAR Surgical Company growing?
STAAR Surgical Company (STAA) saw revenue decline by 23.7% over the past year.
Is STAA profitable?
STAAR Surgical Company (STAA) reported a net loss of $21.0M for fiscal year 2025.
Dividend & Returns
What is STAA's return on equity?
STAAR Surgical Company (STAA) has a return on equity (ROE) of -21.7%. Negative ROE indicates the company is unprofitable.
What is STAAR Surgical Company's free cash flow?
STAAR Surgical Company (STAA) had negative free cash flow of $55.0M in fiscal year 2025, likely due to heavy capital investments.